Literature DB >> 7931235

Monoamine oxidase inhibitors, cognitive functions and neurodegenerative diseases.

J C Delumeau1, D Bentué-Ferrer, J M Gandon, R Amrein, S Belliard, H Allain.   

Abstract

Recent data obtained in animals and in humans suggest that both MAO-A and MAO-B inhibitors present cognitive enhancing properties of possible interest in the treatment of cognitive disorders. In addition, the rational for using selegiline as a neuroprotector in Parkinson's disease may also be applicable in Alzheimer's disease in which a dramatic increase in the MAO-B activity has been reported. It seems then worthwhile to investigate the neuroprotective effect of MAOIs in humans and to assess, furthermore, the real therapeutical benefit of their cognitive enhancing properties.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7931235     DOI： 10.1007/978-3-7091-9324-2_34

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN： 0303-6995


  5 in total

Review 1.  Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease.

Authors:  J Kulisevsky
Journal:  Drugs Aging       Date:  2000-05       Impact factor: 3.923

2.  Curcumin improves D-galactose and normal-aging associated memory impairment in mice: In vivo and in silico-based studies.

Authors:  Md Ashrafur Rahman; Arif Anzum Shuvo; Asim Kumar Bepari; Mehedi Hasan Apu; Manik Chandra Shill; Murad Hossain; Mohammed Uddin; Md Rabiul Islam; Monjurul Kader Bakshi; Javed Hasan; Atiqur Rahman; Ghazi Mohammad Sayedur Rahman; Hasan Mahmud Reza
Journal:  PLoS One       Date:  2022-06-29       Impact factor: 3.752

Review 3.  Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT.

Authors:  Lieven D Declercq; Rik Vandenberghe; Koen Van Laere; Alfons Verbruggen; Guy Bormans
Journal:  Front Pharmacol       Date:  2016-03-31       Impact factor: 5.810

Review 4.  Reactive Oxygen Species: Physiological and Physiopathological Effects on Synaptic Plasticity.

Authors:  Thiago Fernando Beckhauser; José Francis-Oliveira; Roberto De Pasquale
Journal:  J Exp Neurosci       Date:  2016-09-04

5.  The MAO Inhibitor Tranylcypromine Alters LPS- and Aβ-Mediated Neuroinflammatory Responses in Wild-type Mice and a Mouse Model of AD.

Authors:  HyunHee Park; Kyung-Min Han; Hyongjun Jeon; Ji-Soo Lee; Hyunju Lee; Seong Gak Jeon; Jin-Hee Park; Yu Gyung Kim; Yuxi Lin; Young-Ho Lee; Yun Ha Jeong; Hyang-Sook Hoe
Journal:  Cells       Date:  2020-08-28       Impact factor: 6.600
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.